EGFR and non-small cell lung carcinoma: First, many studies showed that TP53/EGFR co-mutations were found in nearly 17%–70% of advanced NSCLC, while our study found TP53 and EGFR co-mutations in only 14.8% (35/236 patients), which had an insufficient sample size to analyze the effect of TP53-specific exons on intracranial metastasis in EGFR-mutated advanced LUAD patients receiving EGFR-TKI therapy.